Skip to search formSkip to main contentSkip to account menu

Revlimid

Known as: Celgene brand of lenalidomide, Revimid 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Objective: To evaluate a novel functional composite endpoint (CEP) based on disability progression and cognitive processing speed… 
2019
2019
Objective: To explore the relationship between plasma neurofilament light chain (NfL) levels and relapsing multiple sclerosis… 
Review
2015
Review
2015
Background Large pivotal randomised controlled trials (RCTs) in rheumatoid arthritis (RA) increasingly employ “adaptive” designs… 
2014
2014
Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow is Associated to Longer Survival in Newly Diagnosed Myeloma… 
Review
2011
Review
2011
A 71-year-old woman with a 9-year history of monoclonal gammopathy of undetermined significance presented with anemia [hemoglobin… 
2009
2009
Using double cytokine knockout donor CD4 cells, in this issue of Blood , Yi and colleagues help clarify the complex role of IFN… 
2008
2008
8587 Background: Typical stem cell mobilization regimens in MM include G-CSF alone or with high-dose cyclophosphamide. Given the… 
2006
2006
Lenolidamide (Revlimid®) is an oral immunomodulatory drug that has been shown to be effective for the treatment of relapsed… 
Review
2005
Review
2005
Summary:High-dose treatment (HDT) with autologous stem cell transplant(s) (ASCT) improved survival, when compared to standard… 
2005
2005
Multiple myeloma (MM) is the second most common hematologic malignancy, affecting approximately 14,000 new patients per year in…